Lexicon Pharmaceuticals, Inc. (LXRX) AI Stock Analysis

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical innovations. Its pipeline centers on orally-delivered small molecule drug candidates targeting critical medical needs. Lead candidate Sotagliflozin has completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes. The company is also developing LX9211, which is in Phase II clinical trials for neuropathic pain. Lexicon operates through strategic collaborations and license agreements with industry partners, including Bristol-Myers Squibb Company and Genentech, Inc., to support research, development, and commercialization efforts.

Lexicon's annual revenue rose from $298,000 in FY2021 to $49.8M in FY2025, reflecting a 5-year revenue CAGR of 15.7%. Gross margin improved from -18371.8% in FY2021 to 99.4% in FY2025. Operating margin was -98.2% in FY2025 compared to -29224.8% in FY2021, while net losses narrowed to -$50.3M from -$200.4M in FY2024. For the trailing twelve months, revenue was $41.5M with an operating margin of -3835.3% and EPS of -$0.16. In the latest quarter ending June 30, 2026, quarterly revenue fell 97.6% year-over-year, and earnings declined 63.4%.

As of June 30, 2026, Lexicon held $190.6M in cash and short-term investments against total debt of $59.3M, yielding net cash of $131.3M. The company reported a current ratio of 13.37 and a debt-to-equity ratio of 0.34, with shareholders' equity of $174.5M. Operating cash flow in FY2025 was -$67.9M, matching free cash flow of -$67.9M. In FY2025, cash used for share buybacks totaled $572,000, while the company's share count increased 193.9% over five years.

Lexicon trades at a price-to-sales multiple of 16.3x, higher than the 4.1x median of its US-listed Healthcare peers. Its enterprise value stands at $783.1M with an EV-to-revenue ratio of 18.9x and an EV-to-EBITDA ratio of 16.6x, compared to the peer median EV-to-EBITDA of 12.0x. Over the past year, LXRX returned 3.4%, trailing the S&P 500 return of 16.8%. Over a 5-year period, the stock fell 75.3%, while the S&P 500 gained 83.0%.

Wall Street coverage includes 3 Strong Buy, 1 Buy, and 2 Hold ratings. The mean price target is $4.55, which is 199.1% above the last close of $1.52. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.17 and revenue of $37.2M. For the following fiscal year, 4 analysts estimate revenue of $16.9M and EPS of -$0.19. Lexicon has beat EPS estimates in 3 of the last 4 quarters, with the next earnings release scheduled for November 5, 2026.

This page is an AI-written research summary of Lexicon Pharmaceuticals, Inc. (LXRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LXRX income statement, LXRX balance sheet, LXRX key metrics, LXRX analyst forecast, LXRX chart. See the LXRX stock overview for the latest quote and news.